SG11201805066RA - Alkyl dihydroquinoline sulfonamide compounds - Google Patents
Alkyl dihydroquinoline sulfonamide compoundsInfo
- Publication number
- SG11201805066RA SG11201805066RA SG11201805066RA SG11201805066RA SG11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- street
- amgen
- compounds
- massachusetts
- Prior art date
Links
- -1 Alkyl dihydroquinoline sulfonamide compounds Chemical class 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 241000219492 Quercus Species 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269518P | 2015-12-18 | 2015-12-18 | |
| PCT/US2016/067617 WO2017106871A1 (en) | 2015-12-18 | 2016-12-19 | Alkyl dihydroquinoline sulfonamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805066RA true SG11201805066RA (en) | 2018-07-30 |
Family
ID=57758767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805066RA SG11201805066RA (en) | 2015-12-18 | 2016-12-19 | Alkyl dihydroquinoline sulfonamide compounds |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10383866B2 (es) |
| EP (1) | EP3390392B1 (es) |
| JP (1) | JP6903663B2 (es) |
| KR (1) | KR102804113B1 (es) |
| CN (2) | CN108602804B (es) |
| AU (1) | AU2016369652B2 (es) |
| CA (1) | CA3008484C (es) |
| CL (1) | CL2018001631A1 (es) |
| CO (1) | CO2018007436A2 (es) |
| CR (1) | CR20180368A (es) |
| EA (1) | EA038286B1 (es) |
| IL (1) | IL259918B (es) |
| MA (1) | MA44065A (es) |
| MX (1) | MX377032B (es) |
| MY (1) | MY197595A (es) |
| NZ (1) | NZ743377A (es) |
| PE (1) | PE20181328A1 (es) |
| PH (1) | PH12018501285A1 (es) |
| SG (1) | SG11201805066RA (es) |
| TN (1) | TN2018000214A1 (es) |
| UA (1) | UA122913C2 (es) |
| WO (1) | WO2017106871A1 (es) |
| ZA (1) | ZA201804033B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| JP2021195367A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| JP7739051B2 (ja) * | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| EP4165032B1 (en) | 2020-06-10 | 2025-04-16 | Amgen Inc. | Heteroalkyl dihydroquinoline sulfonamide compounds |
| CA3228542A1 (en) * | 2021-08-12 | 2023-02-16 | Tyk Medicines, Inc. | Polycyclic compound and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| JP2014521749A (ja) * | 2011-08-17 | 2014-08-28 | アムジエン・インコーポレーテツド | ヘテロアリールナトリウムチャネル阻害剤 |
| EP2788332A1 (en) * | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9776995B2 (en) * | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-12-19 EA EA201891319A patent/EA038286B1/ru unknown
- 2016-12-19 CR CR20180368A patent/CR20180368A/es unknown
- 2016-12-19 AU AU2016369652A patent/AU2016369652B2/en active Active
- 2016-12-19 UA UAA201806895A patent/UA122913C2/uk unknown
- 2016-12-19 MY MYPI2018000912A patent/MY197595A/en unknown
- 2016-12-19 NZ NZ743377A patent/NZ743377A/en unknown
- 2016-12-19 CA CA3008484A patent/CA3008484C/en active Active
- 2016-12-19 US US16/062,606 patent/US10383866B2/en active Active
- 2016-12-19 MX MX2018007432A patent/MX377032B/es active IP Right Grant
- 2016-12-19 SG SG11201805066RA patent/SG11201805066RA/en unknown
- 2016-12-19 KR KR1020187019086A patent/KR102804113B1/ko active Active
- 2016-12-19 PE PE2018001136A patent/PE20181328A1/es unknown
- 2016-12-19 CN CN201680074274.2A patent/CN108602804B/zh active Active
- 2016-12-19 WO PCT/US2016/067617 patent/WO2017106871A1/en not_active Ceased
- 2016-12-19 TN TNP/2018/000214A patent/TN2018000214A1/en unknown
- 2016-12-19 JP JP2018531483A patent/JP6903663B2/ja active Active
- 2016-12-19 CN CN202411119481.8A patent/CN119119017A/zh active Pending
- 2016-12-19 MA MA044065A patent/MA44065A/fr unknown
- 2016-12-19 EP EP16823447.4A patent/EP3390392B1/en active Active
-
2018
- 2018-06-10 IL IL259918A patent/IL259918B/en active IP Right Grant
- 2018-06-14 PH PH12018501285A patent/PH12018501285A1/en unknown
- 2018-06-15 ZA ZA2018/04033A patent/ZA201804033B/en unknown
- 2018-06-15 CL CL2018001631A patent/CL2018001631A1/es unknown
- 2018-07-17 CO CONC2018/0007436A patent/CO2018007436A2/es unknown
-
2019
- 2019-07-12 US US16/510,816 patent/US20200009129A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201805066RA (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201810561YA (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof |